EGLN3 and neoplasm: To determine how PHD3 knockdown interacts with sunitinib treatment, UMRC3-PHD3KD and UMRC3-SC tumor-bearing mice were treated daily with sunitinib after tumor volumes reached approximately 100 mm3.